Rituximab in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease
Part of paid clinical trials in Scottsdale, Arizona.
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study ID
- NCT00003849
- Phase
- PHASE2
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- rituximab — BIOLOGICAL
Study Details
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them. PURPOSE: Phase II trial to study the effectiveness of rituximab in treating patients who have non-Hodgkin's lymphoma or Hodgkin's disease.
Key Dates
- Start date
- Jul 31, 1999
- Status verified
- Jul 2016
- Primary completion
- Feb 28, 2005
- Completion
- Feb 29, 2008
Study Design
- Enrollment
- 39 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: rituximabPatients receive rituximab IV over 4-6 hours on day 1 weekly for 4 weeks. Patients are followed at 1, 3, 6, 9, and 12 months, then every 6 months for 3 years, then annually thereafter.
Primary Outcome Measure
response rate [ Time Frame: Up to 5 years ]
Locations (20)
Find similar trials in Scottsdale, AZ
By research site
CCOP - Scottsdale Oncology Program· Scottsdale, AZCCOP - Illinois Oncology Research Association· Peoria, ILCCOP - Carle Cancer Center· Urbana, ILCCOP - Cedar Rapids Oncology Project· Cedar Rapids, IACCOP - Iowa Oncology Research Association· Des Moines, IASiouxland Hematology-Oncology· Sioux City, IA
Related Studies
- 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With CancerRecruiting · Barbara Ann Karmanos Cancer Institute · Detroit, Michigan
- A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)PHASE1/PHASE2 · Recruiting · Merck Sharp & Dohme LLC · Aurora, Colorado
- Study of Ruxolitinib in Relapsed or Refractory T or NK Cell LymphomaPHASE2 · Recruiting · Memorial Sloan Kettering Cancer Center · Miami, Florida
- Myeloablative Allo HSCT With Related or Unrelated Donor for Heme DisordersPHASE2 · Recruiting · Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota